Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8918756 | 0.98 | ATM (0.50) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL8432804 | 0.93 | DRD4 (0.50) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL17445905 | 0.89 | ATM (0.60) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL1784442 | 0.86 | TAAR1 (0.60) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL17465617 | 0.86 | ATM (0.58) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL7898603 | 0.86 | ATM (0.58) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL7679458 | 0.85 | LSS (0.61) | L3MBTL1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL30624645 | 0.84 | TAAR1 (0.58) | ATML3MBTL1DRD4DRD2DRD3 | |
| SCHEMBL18235025 | 0.84 | DRD4 (0.57) | ATML3MBTL1DRD4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL7686335 | 0.83 | LSS (0.60) | L3MBTL1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | SIRIGEN II LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-12253525-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-18 | — | — | US | disclosed |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| US-20240272166-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN II LIMITED (GB) | 2024-08-15 | — | — | US | disclosed |
| EP-2526138-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| EP-3981819-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| US-20120252986-A1 | SIGNAL AMPLIFIED BIOLOGICAL DETECTION WITH CONJUGATED POLYMERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-10-04 | — | — | US | disclosed |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011091086-A1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010151807-A1 | SIGNAL AMPLIFIED BIOLOGICAL DETECTION WITH CONJUGATED POLYMERS | SIRIGEN, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151807-A1 | SIGNAL AMPLIFIED BIOLOGICAL DETECTION WITH CONJUGATED POLYMERS | SIRIGEN, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12253525-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | ATM 3658/4885L3MBTL1 3469/4885DRD4 3716/4885 |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | ATM 3658/4885L3MBTL1 3469/4885DRD4 3716/4885 |
| US-12235274-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
| US-12345713-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
| US-12111321-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
| US-12241898-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
| US-20260063640-A1 | Reagents for Directed Biomarker Signal Amplification | RNGTT, RNMT, DNMT3L | ATM 3723/4885L3MBTL1 61/4885DRD4 3669/4885 |
| US-20240272166-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | ATM 3658/4885L3MBTL1 3469/4885DRD4 3716/4885 |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | ATM 3658/4885L3MBTL1 3469/4885DRD4 3716/4885 |
| US-12153050-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | ATM 3275/4885L3MBTL1 3113/4885DRD4 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.